Relmada Therapeutics, Inc. (RLMD) announced a significant underwritten public offering on November 4, 2025, expected to generate approximately \(100 million in net proceeds. The offering, managed by Jefferies LLC and Leerink Partners LLC, involves the sale of Common Stock (up to 40,142,000 shares) and Pre-Funded Warrants (up to 5,315,000). Underwriters purchased shares at \)2.0680 and warrants at \(2.0670. Insiders, including the CEO and CFO, demonstrated confidence by committing to purchase approximately \)2.6 million of Common Stock in the transaction.
Proceeds are designated for general corpor
...